Yuldoshevich, Yusupov Ziyodulla, Irekovich, Lutfullin Said, ugli, Rakhmatillaev Rabbonjon Nomoz (2025) COMPARATIVE CHARACTERISTICS OF CLASSICAL AND NEW ORAL ANTICOAGULANTS. Multidisciplinary Journal of Science and Technology.
To'liq matn arxivda mavjud emas — maqolaning asl manbasiga havola pastda berilgan.Annotatsiya
This article presents a comparative analysis of classical and new oral anticoagulants, highlighting their mechanisms of action, pharmacokinetic properties, clinical applications, advantages, and limitations. Classical anticoagulants, such as warfarin, have been widely used for decades but require regular monitoring and dietary restrictions. In contrast, novel oral anticoagulants (NOACs), including rivaroxaban, apixaban, and dabigatran, offer improved safety profiles, predictable pharmacokinetics, and fewer interactions. The article emphasizes the importance of individualized patient care when choosing the appropriate anticoagulant therapy and outlines current clinical guidelines and research findings related to anticoagulation management.
| Hujjat turi: | Maqola |
|---|---|
| Mualliflar: | Muallif Email Yuldoshevich, Yusupov Ziyodulla UNSPECIFIED Irekovich, Lutfullin Said UNSPECIFIED ugli, Rakhmatillaev Rabbonjon Nomoz UNSPECIFIED |
| Jurnal / Nashr: | Multidisciplinary Journal of Science and Technology |
| Nashriyot: | Center for Tech and Media Research |
| Sana: | 9 Iyun 2025 |
| DOI / ID: | oai:ojs.pkp.sfu.ca:article/3911 |
| Kalit so'zlar: | oral anticoagulants, warfarin, novel oral anticoagulants, NOACs, rivaroxaban, apixaban, dabigatran, thrombosis prevention, anticoagulation therapy, clinical comparison. |
| Mavzular: | ?? oral anticoagulants, warfarin, novel oral anticoagulants, NOACs, rivaroxaban, apixaban, dabigatran, thrombosis prevention, anticoagulation therapy, clinical comparison. ?? |
| Eslatma: | Imported from MJST Journal (OAI id oai:ojs.pkp.sfu.ca:article/3911) |
| URI: | https://arxiv.universalpublishings.com/id/eprint/60089 |
![[pin missing: title]](/style/images/action_view.png)